Median pre-treatment NF-kB activity was significantly lower in pre-B ALL versus both T-ALL patients (p = 0.001) and AML patients (p < 0.001) (Fig. 4a, Table 2), while blast percentages were similar for these groups. The gene discussed is NFKB1; the disease is acute myeloid leukemia.